Takeda retains The Remedy for European events

Takeda Europe has re-appointed marketing firm The Remedy to run its pan-European and international meetings for 2007.

The Remedy, which is the medical education division of Fleishman-Hillard in London, beat off three other contenders to win the one-year contract, worth around £750,000.

The contract extension will continue The Remedy's work on medical meetings to support Takeda's diabetes treatment Actos, its hypertensive Blopress and its gonadotrophin-releasing hormone, leuprorelin.

Further projects on other drugs in Takeda's research pipeline are also being considered  but no timeline has yet been given.

Takeda Europe first awarded a two-year contract to The Remedy in August 2004 and David Roberts, Takeda's European marketing director said the two companies had forged a strong partnership in high quality medical education programmes.

Now Takeda can benefit from another year with more enhancements expected from a team that delivers on budget, on time and on brief, he said.

Takeda is one of the top 15 pharmaceutical companies in the world and achieved global sales of  $8.3 billion last year. Its top selling drug, the acid reflux disease proton-pump inhibitor Prevacid, made $3.48 billion in 2005.

The Remedy has its headquarters in Covent Garden, London and is part of the Fleishman Hillard group, which is itself owned by the Omnicom Group. The Remedy focuses on the development and execution of strategic medical education programmes for pharmaceutical and medical device companies.